April 14, 2026 —
Grace Science announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100, an investigational AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency, an ultra-rare and life-threatening genetic disorder with no approved therapies.
The RMAT designation is supported by early clinical evidence from an ongoing open-label, single-arm Phase 1/2/3 clinical trial evaluating GS-100 in pediatric patients. According to the company, patients treated for at least 52 weeks have demonstrated improvements in motor function and cognitive abilities, including gains in sitting, standing, and assisted walking, as well as enhanced attention and caregiver interaction. These early signals suggest potential functional benefit in a disease characterized by severe neurological impairment.
GS-100 is designed as a one-time gene replacement therapy using an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the human NGLY1 gene. By restoring expression of the missing enzyme, the therapy aims to address the underlying cause of disease rather than managing symptoms. The clinical trial is evaluating long-term safety, tolerability, and efficacy across multiple dose levels, with the Phase 3 portion focusing on a 1e15 vg per individual dose.
The RMAT designation, established to expedite development of regenerative medicines for serious conditions, provides Grace Science with enhanced regulatory interaction and the potential for accelerated approval pathways. GS-100 has previously received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, and Fast Track, as well as inclusion in the FDA’s START pilot program, further supporting streamlined development.
NGLY1 Deficiency is a rare genetic disorder caused by loss-of-function mutations in the NGLY1 gene, leading to a complex neurological syndrome that manifests early in life. Patients experience global developmental delay, movement disorders, and cognitive impairment, with limited treatment options currently available. The advancement of GS-100 into later-stage clinical evaluation represents a significant step toward a potential disease-modifying therapy for this underserved patient population.
